Maxim Group analyst Anthony Vendetti maintained a Buy rating on Electrocore (ECOR – Research Report) yesterday and set a price target of $1.00. The company’s shares closed yesterday at $0.25.
According to TipRanks, Vendetti is an analyst with an average return of -4.4% and a 31.60% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Nephros, Pulse Biosciences, and Venus Concept.
Electrocore has an analyst consensus of Moderate Buy, with a price target consensus of $1.00.
See Insiders’ Hot Stocks on TipRanks >>
ECOR market cap is currently $23.49M and has a P/E ratio of -0.83.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
electroCore, Inc. is a commercial-stage bio-electronic medicine company, with a platform non-invasive vagus nerve stimulation therapy focuses on neurology and rheumatology. The company’s therapy, gammaCore, has pharmacologic effects on the peripheral and central nervous systems, which modulate neurotransmitters and immune function. It focuses on acute treatment of migraine and episodic cluster headache. The company was founded by Joseph P. Errico, Steve Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Morris Plains, NJ.
Read More on ECOR:
